DURHAM, N.C., United States and BEIJING, China – February 28, 2022 – Brii Biosciences Limited (“Brii Bio” or the “Company”, stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens, today announced its participation in the following conferences in March 2022. Details of the conferences and management presentations are as follows:

Morgan Stanley 2022 Hong Kong Summit (Virtual)

One-on-one and small group meetings: March 22-24, 2022

Participants: Management team and IR

For more information, please contact your Morgan Stanley representative.

Huachuang Securities 2022 Spring Conference

One-on-one and small group meetings: 14:30-16:30 Beijing time, March 1, 2022

Venue: Grand Hyatt Shanghai

Participants: Management team and IR

For more information, please contact your Huachuang Securities representative.

About Brii Bio

Brii Biosciences Limited (“Brii Bio”, or the “Company”, stock code: 2137.HK) is a biotechnology company based in China and the United States committed to advancing therapies for significant infectious diseases, such as hepatitis B, COVID-19, human immunodeficiency virus (HIV) infection, multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases, which have significant public health burdens in China and worldwide. For more information, visit www.briibio.com.

Media Inquiry:
media@briibio.com
Summer Li (China)
+86-135-2191-1607
Ben Shannon (U.S.)
+1-919-360-3039

Investor Inquiry:
ir@briibio.com
Chris Fang
+86-139-1692-8049